ReviewAnnual review of medicine2018
Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Review in Annual review of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Polymersome-based nanomedicine for combined cancer therapy.Drug delivery · 2026Review
- Cardiopulmonary Complications in Obese Patients with Gynecologic Cancer: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Combined influence of nutritional and inflammatory status on mortality in cancer survivors complicated with cardiovascular disease.BMC cardiovascular disorders · 2025Article
- Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.Journal of clinical medicine · 2024Review
- Multivitamin use and all-cause and cause-specific mortality in cancer survivors.British journal of cancer · 2024Article
- Proportion and number of incident cancer deaths in coronary artery disease.Cancer medicine · 2023Article
- Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Caspase-1 Regulates the Apoptosis and Pyroptosis Induced by Phthalocyanine Zinc-Mediated Photodynamic Therapy in Breast Cancer MCF-7 Cells.Molecules (Basel, Switzerland) · 2023Article
- Evidence of sex differences in cancer-related cardiac complications in mouse models of pancreatic and liver cancer.Physiological reports · 2023Article
- Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.Biomedicines · 2023Review
- Where are We Going with Natural Products? Exploring the True Potential of New Plant-Based Drugs in the Cardiovascular Field.Arquivos brasileiros de cardiologia · 2022Article
- Basic cardiovascular risk assessment in naïve patients with colon cancer.Experimental and therapeutic medicine · 2022Article
- Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments.Frontiers in cardiovascular medicine · 2022Review
- Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease.The Journal of clinical investigation · 2021Review
- The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.Heart failure reviews · 2021Review
- Acquired and modifiable cardiovascular risk factors in patients treated for cancer.Journal of thrombosis and thrombolysis · 2021Review
- Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward.Cancer treatment and research communications · 2021Review
- Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology Service.Frontiers in cardiovascular medicine · 2021Article
- Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingly important. In addition to outlining the CV effects of commonly used cancer therapies and their consequences for long-term survivorship, this review highlights the recent efforts to improve the risk prediction and prevention of CV toxicity through the evaluation of sensitive measures for early toxicity detection and the implementation of cardioprotective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.